DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

APPROVED IN CHILDREN WITH
ASTHMA AS YOUNG AS 6 YEARS

Learn more
DUPIXENT MAY BE
APPROPRIATE FOR

your moderate-to-severe asthma patients characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma

  • Exacerbation requiring hospitalization/ED visit in the past year
  • 2 courses of oral corticosteroids (OCS) in the past year despite maximum inhaler therapy
  • Still uncontrolled on medium- or high-dose inhaled corticosteroids (ICS) + LABA
  • Elevated EOS with or without IgE/FeNO
  • Impaired lung function and decreased quality of life

DUPIXENT MAY OFFER ASTHMA
SYMPTOM RELIEF TO YOUR
APPROPRIATE
PATIENTS, INCLUDING:

Allergic asthma
patients with
elevated eosinophils

OCS-dependent asthma patients—DUPIXENT is the only biologic indicated for this
patient population1

Patients with coexisting diseases, such as atopic dermatitis or chronic rhinosinusitis with nasal polyposis1,2

Extensive clinical trial and real-world experience across indications

>6800 patients studied and >450K patient prescriptions3

DUPIXENT has proven efficacy and a demonstrated safety profile in nearly 3000 patients with moderate-to-severe asthma1

Exacerbation reduction1

OCS reduction4

Rapid and sustained
breathing relief1,5,a

Demonstrated
safety profile1

Asthma control
and quality of life1

At-home or in-office
administration1,b

a ~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg + SOC (n=264). Up to 470 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 200 mg + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (Trial 2, EOS ≥300 cells/µL, secondary endpoint). 320 mL improvement from baseline in pre-bronchodilator FEV1 at Week 12 with DUPIXENT 200 mg + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (Trial 2, ITT population, primary endpoint). In Trial 2, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV1 in patients with baseline blood eosinophil levels <150 cells/µL taking DUPIXENT 200 mg + SOC.1

b A patient or caregiver may inject DUPIXENT after training in subcutaneous injection technique.1

Most Common
Adverse Reactions

The most common adverse reactions (incidence ≥1%) in patients with asthma were injection site reactions, oropharyngeal pain, and
eosinophilia. In Trials 1 and 2, the proportion of subjects who discontinued treatment due to adverse events was 4% of the placebo + SOC
group, 3% of the DUPIXENT 200 mg Q2W + SOC group, and 6% of the DUPIXENT 300 mg Q2W + SOC group.1

Trial Designs and Results

DUPIXENT is not a steroid1,f

fDupilumab is a dual inhibitor of IL-4 and IL-13 signaling. The mechanism of dupilumab action in asthma has not been definitively established.

Frequently asked questions about DUPIXENT

DUPIXENT is a biologic therapy and has a unique mechanism of action. DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, inhibiting two key sources of Type 2 inflammation in asthma. DUPIXENT is not an immunosuppressant or steroid. The mechanism of dupilumab action in asthma has not been definitively established.1

SEE HOW DUPIXENT WORKS

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.1

SEE THE EFFICACY AND SAFETY DATA OF DUPIXENT EXPLORE APPROPRIATE PATIENT TYPES

DUPIXENT is typically prescribed by a specialist, such as an allergist or a pulmonologist. If you have patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma who you think might be appropriate for DUPIXENT, consider referring them to an asthma specialist.1

For help finding a specialist in your area, use the Heathgrades® tool below.

Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT.6,g Coverage varies by type and plan.

With the DUPIXENT formulary status tool, you can see which insurance plans offer coverage for DUPIXENT in your area. Contact the health plan or DUPIXENT MyWay® to verify coverage for a specific patient.

gMMIT Lives as of August 2021.

CHECK FORMULARY
STATUS FOR DUPIXENT
IN YOUR AREA

For patients with a valid prescription for DUPIXENT, support is available through the DUPIXENT MyWay® patient support program. Patients who enroll can receive:

  • Insightful tips and tools to help them along the way
  • Supplemental injection training virtually or over the phone
  • Financial assistance for eligible patients
  • Assistance with insurance questions
  • Assistance locating a specialty pharmacy that can dispense DUPIXENT
LEARN MORE ABOUT THE SUPPORT OFFERED BY DUPIXENT MyWay

DUPIXENT provides eligible patients with access supportg,h

We're committed to helping ensure patients have access to DUPIXENT and are provided with assistance in navigating the insurance process.

Overall, ~98% of commercially insured patients nationally are covered for DUPIXENT.6,g

Coverage varies by type of plan.

gMMIT Lives as of August 2021.

hEligible patients subject to program restrictions.

iApproval is not guaranteed. Program has an annual maximum of $13,000. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. This program is not valid where prohibited by law, taxed or restricted. DUPIXENT MyWay reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Any savings provided by the program may vary depending on patients' out-of-pocket costs. The program is intended to help patients afford DUPIXENT. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms. Additional terms and conditions apply.

Refer your appropriate asthma patients to a specialist today

Partner with an asthma specialist to help your patients. Use the Healthgrades®
tool to easily find nearby specialists.

Sanofi US and Regeneron neither endorse nor recommend any particular physician, and
search results do not include a comprehensive list of doctors in your area.